Compare KELYB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | ASMB |
|---|---|---|
| Founded | 1946 | 2005 |
| Country | United States | United States |
| Employees | 5570 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.9M | 440.0M |
| IPO Year | N/A | 2010 |
| Metric | KELYB | ASMB |
|---|---|---|
| Price | $15.18 | $28.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 86.9K | ★ 91.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.72 | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $7.76 |
| 52 Week High | $125.00 | $39.71 |
| Indicator | KELYB | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 49.61 |
| Support Level | $11.79 | $26.50 |
| Resistance Level | $18.66 | $31.11 |
| Average True Range (ATR) | 1.39 | 1.84 |
| MACD | -0.22 | 0.11 |
| Stochastic Oscillator | 54.21 | 57.55 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services to a diverse group of clients operating in the Americas, Europe, and the Asia-Pacific region across various industries. The company's reportable segments are: Enterprise Talent Management, Science, Engineering and Technology, and Education. Maximum revenue is generated from its Enterprise Talent Management segment, which delivers temporary staffing, outcome-based, and permanent placement services focused on light industrial, contact center, and office and clerical specialties in North America across various industries. It also provides talent supply chain and workforce talent solutions, including MSP, RPO, and PPO solutions to its clients. Geographically, it derives key revenue from the USA.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.